Follow the Data: Make decisions preclinically, when comparing subtle gene edits in NK cell therapies1

Research Area: Cell engineering & therapy

Development Stage: Discovery

Goal: Reveal choice in NK cell therapy by identifying differences resulting from subtle gene edits

[unex_ce_button id="content_10khx0ih9,column_content_611g46odk" button_text_color="#ffffff" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px" button_bg_color="#29acd8" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#29acd8" button_border_radius="0px" button_text_hover_color="#ffffff" button_text_spacing_hover="1px" button_bg_hover_color="#9cc9d8" button_border_hover_color="#9cc9d8" button_link="https://www.isoplexis.com/request-a-seminar" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Request a seminar
to follow our data >[/ce_button]

How our single-cell systems are making a difference

Solution:  PSI revealed potency differences in gene edited NK cell therapies to enhance decision making

Finding: These critical potency differences between edited and wildtype cells also correlated with in vivo mouse response to therapy

Follow the data

Polyfunctionality and PSI underscore significant differences between gene-edited KO- iPSC-NK cells and wild type cells. The CISH-/- knock- out cells showed enrichment of polyfunctional  cell subsets compared to the wild type samples (left).

Similarly, the PSI of the knock-out cells is substantially (10x) higher than of the wild type (right) indicating that CIS plays a key role in regulating NK cell activation-induced exhaustion and that Notch activation prevents this exhaustion and enables production of functionally hyperactive NK cells.1

[unex_ce_button id="content_om95el0ye,column_content_g32kkdowi" button_text_color="#424242" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px " button_bg_color="#c9c9c9" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#c9c9c9" button_border_radius="0px" button_text_hover_color="#424242" button_text_spacing_hover="1px" button_bg_hover_color="#e8e8e8" button_border_hover_color="#e8e8e8" button_link="https://www.isoplexis.com/CellT-P" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Download application note
to learn more >[/ce_button]

IsoPlexis finds critical differences

At day 35, CISH-/- iPSC-NK demonstrate better anti-tumor activity in vivo. NSG mice were inoculated with the human leukemia cell line Molm13, expressing the firefly luciferase gene. One day after tumor transplant, mice were either left untreated or were treated with either WT-iPSC-NK or KO-iPSC-NK cells.

35 days after inoculation, two out of four untreated mice (left) had died and the other two showed significant tumor load, WT-iPSC- NK mice (middle) showed substantial tumor growth while in CISH KO-iPSC-NK mice (right), tumor growth is nearly absent. These results are consistent with 10x higher in vitro PSI of CISH KO-iPSC-NK cells relative to wild type cells presented in the previous figure.1